STOCK TITAN

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) will announce its financial results for Q4 and the year ending December 31, 2022, on February 23, 2023, before U.S. markets open. Management will discuss the results and future expectations during a conference call at 8:30 am ET on the same day, which can be accessed via registration online. Alnylam is recognized for pioneering RNA interference (RNAi) therapeutics with products like ONPATTRO, AMVUTTRA, and others, alongside a robust pipeline under its "Alnylam P5x25" strategy aimed at innovative treatments for various diseases. More information is available on their website.

Positive
  • Continuing innovation in RNAi therapeutics with a strong product pipeline.
  • Effective execution of the 'Alnylam P5x25' strategy to deliver transformative medicines.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.

Management will provide an update on the Company and discuss fourth quarter and year-end 2022 results as well as expectations for the future via conference call on Thursday, February 23, 2023 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI050ad56309204f0a836ec037dd396473. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals report its Q4 2022 financial results?

Alnylam Pharmaceuticals will report its Q4 2022 financial results on February 23, 2023.

What conference call will Alnylam conduct regarding its financial results?

Alnylam will host a conference call on February 23, 2023, at 8:30 am ET to discuss its financial results and future expectations.

What is the focus of Alnylam Pharmaceuticals' pipeline?

Alnylam's pipeline focuses on RNA interference (RNAi) therapeutics for various rare and prevalent diseases.

What are Alnylam Pharmaceuticals' commercial products?

Alnylam's commercial products include ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio.

Where can I find more information about Alnylam Pharmaceuticals?

More information about Alnylam can be found on their official website at www.alnylam.com.

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

ALNY Rankings

ALNY Latest News

ALNY Stock Data

30.67B
128.18M
0.43%
98.2%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE